Leadership

John McLaughlin

Chief Executive Officer

John P. McLaughlin has served as our Chief Executive Officer since December 2008, when the Company spun-off Facet Biotech Corporation (Facet Biotech). From December 2008 until September 2017, Mr. McLaughlin served the Company as both President and Chief Executive Officer.

Mr. McLaughlin was elected a director of the Company in October 2008 and from November 6, 2008 until the spin-off on December 18, 2008, he served as a Senior Advisor to the Company. He was the Chief Executive Officer and a director of Anesiva, Inc., formerly known as Corgentech, Inc., a publicly-traded biopharmaceutical company, from January 2000 to June 2008. From December 1997 to September 1999, Mr. McLaughlin was President of Tularik Inc., a biopharmaceutical company. From September 1987 to December 1997, Mr. McLaughlin held a number of senior management positions at Genentech, Inc., a biopharmaceutical company, including Executive Vice President and General Counsel. From January 1985 to September 1987, Mr. McLaughlin was a partner at a Washington, D.C. law firm specializing in food and drug law. Prior to that, Mr. McLaughlin served as counsel to various subcommittees in the United States House of Representatives, where he drafted numerous measures that became FDA laws. Mr. McLaughlin co-founded and served as Chairman of the Board of Directors of Eyetech Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company subsequently bought by OSI Pharmaceuticals, Inc. He also co-founded and served as a director of Peak Surgical, Inc., a privately-held medical device company subsequently purchased by Medtronic, Inc.   He also served as a director of AxoGen, Inc., Adverum Biotechnologies, Inc. and Seattle Genetics, publicly-traded biopharmaceutical companies.  He received a B.A. from the University of Notre Dame and a J.D. from the Catholic University of America.  Mr. McLaughlin possesses a strong understanding of the biotechnology industry and has experience in development, regulation and commercialization of drugs, corporate licensing and litigation that the Company values. In addition, Mr. McLaughlin provides strategic guidance to our management team and the Board.

Read more

Dominique Monnet

President

Dominique Monnet, our President, joined the Company in September 2017.  Before joining PDL, Mr. Monnet served as senior vice president and chief marketing officer of Alexion Pharmaceuticals in 2014 to 2015 where he was responsible for commercial operations in the U.S. and Latin America and oversaw new products and global business operations functions.

 From 2002 to 2013, he was a senior executive at Amgen Inc. where he served in a number of key commercial leadership positions in the U.S. and internationally. As vice president and general manager for Amgen’s Inflammation Business Unit in 2011 to 2013, he was responsible for accelerating the growth of the Enbrel® franchise in the highly competitive U.S. market. Prior to this, he served as vice president and head of Amgen’s Global Marketing and Commercial Development, where he led the marketing strategy and new product launches in a wide range of therapeutic areas. From 2002 through 2006, Mr. Monnet was based in Zug, Switzerland, where he served as Amgen’s vice president of International Marketing and Business Operations, building Amgen’s international commercial capability and leading the creation of its successful international franchises in oncology and nephrology. Before joining Amgen, Dominique held positions of increasing responsibility in line commercial management and global marketing over 19 years at Schering-Plough – including General Manager of its affiliate in the UK and Republic of Ireland — Ciba-Geigy and Alza Corporation. Mr. Monnet holds a business degree from EDHEC Business School in Lille, France, and an MBA from INSEAD in Fontainebleau, France.
Read more

Peter Garcia

Vice President and Chief Financial Officer

Peter Garcia, our Vice President and Chief Financial Officer, joined the Company in May, 2013. Before joining PDL, Mr. Garcia served as CFO of BioTime, Inc., which he joined in 2011. Between the years of 1996 and 2011, Mr. Garcia was CFO of six biotech and high-tech companies, including Marina Biotech, Nanosys, Nuvelo, Novacept, IntraBiotics Pharmaceuticals and Dendreon Corporation.

While at these companies, he raised over $550 million, led multiple merger and acquisition transactions, and managed multiple functions including finance, accounting, treasury, investor relations, corporate communications, IT and facilities. From 1990 to 1996, he was a finance executive with Amgen. Mr. Garcia holds a B.A. in economics and sociology with honors from Stanford University and an MBA with an emphasis in finance and accounting from UCLA.
Read more

Christopher Stone

Vice President and General Counsel

Christopher Stone, our Vice President, General Counsel and Secretary, joined the Company in February 2009. He brings more than 27 years of legal experience to the role. Before joining PDL, Mr. Stone served as Vice President of Legal Affairs and Corporate Secretary at LS9, an advanced biofuels development company, where his work included a focus on intellectual property protection, research collaborations and licensing.

Prior to that time, he was Vice President of Intellectual Assets USA at Danisco A/S, a global producer of food ingredients, enzymes and bio-based solutions. From 1994 to 2005, Mr. Stone was with Genencor International, a biotechnology company which was acquired by Danisco in 2005, most recently as Vice President of Intellectual Property and General Patent Counsel. At Genencor, he handled all intellectual property matters, including developing and implementing an overall strategy for its domestic and international patent estate of approximately 3,700 patents and patent applications, intellectual property transactions including licensing and research collaboration management, and managed multiple litigation and interference proceedings and numerous European patent oppositions. Mr. Stone received a J.D. from the National Law Center at George Washington University and a B.S. in Biochemistry from the University of Massachusetts. He is an active member of the District of Columbia Bar, Nevada Bar and California Bar, and was admitted to practice before the United States Patent & Trademark Office in 1992.
Read more

Danny Hart

Vice President, Business Development

Danny Hart, our Vice President, Business Development, focuses on the Company’s investment activity by identifying, evaluating, structuring and completing the Company’s alternative, non-dilutive financing investments (structured debt, synthetic royalty, royalty monetization) for late-stage pharmaceutical, device and diagnostic companies.

Additionally, Mr. Hart monitors and restructures, when necessary, PDL’s ongoing financing investments.  He joined PDL BioPharma in January 2010 as the Company’s Corporate Counsel.  Since joining the Company, Mr. Hart was promoted to Associate General Counsel and Assistant Secretary in April 2011 and then to Deputy General Counsel and Assistant Secretary in January 2012.  In September 2014, Danny was elevated to Vice President, Business Development, a non-legal role evaluating and structuring PDL’s investment transactions.  From 2006 until he joined the Company Danny worked as an associate with Hogan & Hartson LLP (now Hogan Lovells US LLP), a leading international law firm, where his practice focused on securities, corporate governance and mergers and acquisitions.  Before joining Hogan & Hartson Danny began his legal career at Skadden, Arps, Slate, Meagher & Flom LLP, a leading international law firm, where he focused on corporate restructurings.  Danny received a J.D. from Vanderbilt University Law School and a B.A. from the University of Washington in Seattle.
Read more

Steffen Pietzke

Vice President, Finance, and Chief Accounting Officer

Steffen Pietzke, currently our Vice President, Finance, and Chief Accounting Officer, joined the company in June, 2015. Prior to PDL, Mr. Pietzke was a Senior Manager with Ernst & Young LLP (EY) since 2013. He provided audit and related financial services to both public and private companies in the U.S., Europe and China.

Prior to joining EY, Mr. Pietzke was with PricewaterhouseCoopers LLP for more than 12 years, most recently as a senior manager. He is highly regarded at these public accounting firms for his technical expertise and was focused on specific complex areas such as revenue recognition, financial instruments, derivatives, stock-based compensation and public offerings. Mr. Pietzke is a licensed Certified Public Accountant, a member of the American Institute of Certified Public Accountants and holds a Bachelor of Business Science degree in Accounting with honors from the University of Sciences in Offenburg, Germany.
Read more

Nathan Kryszak

Deputy General Counsel

Nathan Kryszak, our Deputy General Counsel and Assistant Secretary joined the Company in August 2014 as Senior Counsel. Since joining the Company, Mr. Kryszak was appointed Assistant Secretary in September 2014 and promoted to Deputy General Counsel effective January 2017.

He brings more than a decade of legal experience to the role. From 2010 until he joined the Company, Mr. Kryszak worked as a senior associate in the banking practice of White & Case LLP, a leading international law firm. Before joining White & Case, Mr. Kryszak worked as an associate in the corporate department at Cahill Gordon & Reindel LLP, where he focused on corporate finance. Prior to that, Mr. Kryszak began his career as a judicial clerk in the United States Court of Federal Claims. Mr. Kryszak received a J.D. from the University of Washington School of Law, an LL.M. from Georgetown University Law Center and a B.A. from Georgetown University. He is an active member of the Nevada Bar (company counsel) and California Bar and an inactive member of the New York Bar.
Read more

Paul Edick

Director

Mr. Edick brought over 35 years of experience in the life sciences industry to PDL when he was elected to the board in September of 2015. Mr. Edick is currently the President and CEO of Xeris Pharmaceuticals, Inc. Prior to Xeris, he was managing partner of 3G Advisors, LLC.

From July 2010 to November 2014, he served as chief executive officer and a board member of Durata Therapeutics, Inc. Prior to his term at Durata, Mr. Edick was chief executive officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus investment search vehicle, from 2008 to 2010 and prior to that was chief executive officer at MedPointe Healthcare, Inc., a position he assumed in 2006 having been their president of pharmaceutical operations from 2002. He also held a number of senior positions at GD Searle & Company, and at Pharmacia Corporation following its acquisition of the company, culminating in his appointment as Pharmacia’s group VP and president, Asia Pacific/Latin America. Mr. Edick currently serves on the boards of directors for Sucampo Pharmaceuticals Inc., NewLink Genetics Corporation and, Neos Therapeutics, Inc. all of which are public companies. He also serves on the Board of the private company Amerita, Inc. Mr. Edick holds a B.A. in Psychology from Hamilton College. Mr. Edick brings to the Board over 35 years of experience in the life sciences industry, including extensive development and commercial expertise from his chief executive officer positions at several companies, including most recently at Xeris Pharmaceuticals, Inc. and Durata Therapeutics, Inc.
Read more

David Gryska

Director

David W. Gryska was elected a director in March 2014.  Mr. Gryska is currently serving as Executive Vice President and Chief Financial Officer for Incyte Corporation. Prior to Incyte Mr. Gryska served as Chief Operating Officer and a director of Myrexis, Inc., a biotechnology company, from May 2012 to December 2012.

 From  2006 to 2010, he was Senior Vice President and Chief Financial Officer of Celgene Corporation, a biopharmaceutical company.  From  2004 to 2006, he was a principal at Strategic Consulting Group, where he provided strategic consulting to early-stage biotechnology companies.  Previously, Mr. Gryska served at Scios, Inc., a biopharmaceutical company, as Senior Vice President and Chief Financial Officer from 2000 to 2004, and as Vice President of Finance and Chief Financial Officer from 1998 to 2000.  Scios was acquired by Johnson & Johnson in 2003.  From 1993 to 1998, he served as Vice President, Finance and Chief Financial Officer at Cardiac Pathways, a medical device company later acquired by Boston Scientific Corporation.  Prior to Cardiac Pathways, Mr. Gryska served as a partner at Ernst & Young (EY). During his eleven years at EY, he focused on technology industries, with an emphasis on biotechnology and healthcare companies. Mr. Gryska holds a B.A. in Accounting and Finance from Loyola University and an M.B.A. from Golden Gate University.  He also serves on the Board of Directors of Seattle Genetics.  Mr. Gryska has over 20 years’ experience as a chief financial officer for several public companies. Prior to these roles, he was an audit partner at EY. Mr. Gryska brings to the Board extensive knowledge of, and experience in, the application of accounting principles and the financial reporting process, particularly, in the health care sciences industry. In addition, Mr. Gryska fills the role of an “Audit Committee Financial Expert” (as defined in applicable SEC rules) for the Company.
Read more

Jody Lindell

Director

Jody S. Lindell was elected a director of the Company in March 2009. Ms. Lindell is President and Chief Executive Officer of S.G. Management, Inc., an asset management company she has headed since 2000. Prior to that, Ms. Lindell was a partner with KPMG LLP where she served as Partner-In-Charge of the Industrial Markets and Healthcare

and Life Sciences practices for the Western Area. Through September 2007, she served as a director and on the Audit and Director’s Loan Committees for First Republic Bank, which was a publicly-traded financial institution that has since been acquired. Ms. Lindell continues to serve on the Advisory Board and Advisors Loan Committee for First Republic Bank. She has also served as a director of The Cooper Companies since March 2006 and is a Chairperson of its Audit Committee and member of its Audit and Organization and Compensation Committees. She is a Certified Public Accountant (inactive) and holds a B.A. from Stanford University and an M.B.A. from the Stanford Graduate School of Business. The Board values Ms. Lindell’s extensive accounting experience, including 25 years’ experience at KPMG LLP, 16 of which were as an audit partner. Ms. Lindell’s knowledge of accounting principles and financial reporting rules and regulations and oversight of the financial reporting process is valued by the Company in her role as a director, the chairperson of the Audit Committee and an Audit Committee Financial Expert.
Read more

John McLaughlin

Chief Executive Officer

John P. McLaughlin was elected a director of the Company in October 2008 and has served as Chief Executive Officer since December 2008, after the Company spun-off Facet Biotech Corporation (Facet Biotech). From December 2008 until September 2017, Mr. McLaughlin served the Company as both President and Chief Executive Officer.

From November 6, 2008 until the spin-off on December 18, 2008, he served as a Senior Advisor to the Company. He was the Chief Executive Officer and a director of Anesiva, Inc., formerly known as Corgentech, Inc., a publicly-traded biopharmaceutical company, from January 2000 to June 2008. From December 1997 to September 1999, Mr. McLaughlin was President of Tularik Inc., a biopharmaceutical company. From September 1987 to December 1997, Mr. McLaughlin held a number of senior management positions at Genentech, Inc., a biopharmaceutical company, including Executive Vice President and General Counsel. From January 1985 to September 1987, Mr. McLaughlin was a partner at a Washington, D.C. law firm specializing in food and drug law. Prior to that, Mr. McLaughlin served as counsel to various subcommittees in the United States House of Representatives, where he drafted numerous measures that became FDA laws. Mr. McLaughlin co-founded and served as Chairman of the Board of Directors of Eyetech Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company subsequently bought by OSI Pharmaceuticals, Inc. He also co-founded and served as a director of Peak Surgical, Inc., a privately-held medical device company subsequently purchased by Medtronic, Inc.   He also served as a director of AxoGen, Inc., Adverum Biotechnologies, Inc. and Seattle Genetics, publicly-traded biopharmaceutical companies.  He received a B.A. from the University of Notre Dame and a J.D. from the Catholic University of America.  Mr. McLaughlin possesses a strong understanding of the biotechnology industry and has experience in development, regulation and commercialization of drugs, corporate licensing and litigation that the Company values. In addition, Mr. McLaughlin provides strategic guidance to our management team and the Board.
Read more

Dr. Samuel Saks

Director

Dr. Saks was first appointed a director of the Company in September of 2015. He is a board certified oncologist who most recently served as chief development officer for Auspex Pharmaceuticals, Inc., a position he held from 2013 until it was acquired by Teva Pharmaceuticals Industries, Ltd. in May 2015.

He has also served as a board member for Auspex from 2009 to 2015. Prior to Auspex, Dr. Saks was a co-founder of Jazz Pharmaceuticals plc, where he was chief executive officer for six years. Before that, Dr. Saks served as company group chairman of ALZA Corp. (“ALZA”), and then participated as a member of the Johnson & Johnson Pharmaceutical Group Operating Committee upon the merger of J&J and ALZA. Prior to that, Dr. Saks held various positions with ALZA, most recently as its group vice president. Prior to ALZA, Dr. Saks held clinical research and development management positions with Schering-Plough Corporation, Xoma Corp. and Genentech, Inc. Dr. Saks currently serves on the boards of directors of TONIX Pharmaceuticals Holding Corp. which is a publicly-traded pharmaceutical company, as well as private companies Bullet Biotechnology, Inc., Velocity Pharmaceutical Development, LLC., and NuMedii Inc. Dr. Saks holds a B.S. in Biology and an M.D. from the University of Illinois.  Dr. Saks brings over 35 years of experience in biotechnology management to the Board, including extensive product development expertise.
Read more

Paul Sandman

Director

Paul W. Sandman was elected a director of the Company in October 2008. Mr. Sandman served at Boston Scientific Corporation in various management positions from May 1993 to February 2008, most recently as its Executive Vice President, Secretary and General Counsel. From 1984 to April 1993, he served at Wang Laboratories, Inc., most recently as Senior Vice President, General Counsel and Secretary.

Mr. Sandman received his A.B. from Boston College and his J.D. from Harvard Law School. In April 2015 he joined the Business Advisory Board of NuVascular Technologies. As a former general counsel and executive officer of a major, publicly-traded medical technology company, Mr. Sandman provides the Board with experience in corporate governance and the Litigation Committee of the Board with invaluable experience in intellectual property litigation.
Read more

Harold Selick, Ph.D.

Lead Director

Harold E. Selick, Ph.D., was elected a director in August 2009. Currently Dr. Selick is serving as Vice Chancellor of Innovation and Partnerships at the University of California, San Francisco. Prior to that, Dr. Selick has served as Chief Executive Officer and a director of Threshold Pharmaceuticals, Inc., a publicly-traded biotechnology company. From June 2002 until April 2017, where he still serves as Chairman of the Board of Directors.

From June 2002 until July 2007, Dr. Selick also was a Venture Partner of Sofinnova Ventures, Inc., a venture capital firm. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation, a biotechnology company. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as Vice President of Research. Prior to working at Affymax, Dr. Selick held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. As a staff scientist at Protein Design Labs, Inc. (now PDL BioPharma, Inc.), he co-invented technology underlying the creation of fully humanized antibody therapeutics and applied that to PDL’s first product, Zenapax (daclizumab), which was developed and commercialized by Roche for the prevention of kidney transplant rejection. Dr. Selick received his B.A. and Ph.D. degrees from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.

As co-inventor of technology that underlies the Queen et al. patents, Dr. Selick provides the Board with a scientific perspective and a unique appreciation of the Company’s assets. Dr. Selick also provides the Board with operational experience derived from his role as a chief executive officer of a publicly-traded biotechnology company.

Read more